RxDoctor Payments Data

Cryselda Trevino, PA

Physician Assistant · Rockwall, TXNPI 1982243663

Payments from drug & device makers

$8,827in general payments, 2019–2025

Across 402 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$2K
  • AbbVie$1K
  • Lilly USA, LLC$632
  • AstraZeneca$522
  • Boehringer Ingelheim$517
  • Novo Nordisk$516
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$1,20014%
  • Food & beverage$7,62786%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,827 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$49,354
Medicare patients
190
Services billed
932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide80$100,416
OzempicSemaglutide77$77,120
JardianceEmpagliflozin56$64,831
TrulicityDulaglutide29$43,006
EliquisApixaban29$28,958
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$22,437
MyrbetriqMirabegron27$21,551
LinzessLinaclotide17$20,214
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$11,249
EntrestoSacubitril/Valsartan12$9,727
VascepaIcosapent Ethyl16$6,756
SymbicortBudesonide/Formoterol Fumarate14$4,852
Gabapentin127$3,097
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,987
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$632$143,423109 claims
Novo NordiskOzempic$516$77,12077 claims
Boehringer IngelheimJardiance$517$64,83156 claims
PfizerEliquis, Paxlovid$494$30,31846 claims
GSKTrelegy Ellipta$441$22,43733 claims
AbbVieLinzess, Synthroid$1,042$21,79138 claims
Astellas Pharma US IncMyrbetriq$107$21,55127 claims
AstraZenecaSymbicort$522$4,85214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Rockwall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →